I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of precision ...
Hosted on MSN1h
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...
Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic ...
BofA and Leerink acted as joint book running managers for the offering.Discover the Best Stocks and Maximize Your Portfolio: See what stocks ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Q4 2024 . Management View. CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, ...
NeuroPace expects to use approximately $49.5 million of the net proceeds from the offering to repurchase 5,270,845 shares of the Company's common stock held by NeuroPace's significant stockholder, KCK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback